Stockscreener 앱 받기
12.00
2.21%
0.26
시장 영업 전:
12.05
0.05
+0.42%
전일 마감가:
$11.74
열려 있는:
$11.855
하루 거래량:
1.17M
Relative Volume:
0.79
시가총액:
$1.01B
수익:
-
순이익/손실:
$-44.17M
주가수익비율:
-22.81
EPS:
-0.526
순현금흐름:
$-35.14M
1주 성능:
+7.53%
1개월 성능:
-2.52%
6개월 성능:
+53.06%
1년 성능:
+204.57%
1일 변동 폭
$11.86
$12.38
1주일 범위
$10.91
$12.40
52주 변동 폭
$3.55
$26.95
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
명칭
Corvus Pharmaceuticals Inc
전화
(650) 900-4520
주소
901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA
Compare CRVS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
12.00 | 1.00B | 0 | -44.17M | -35.14M | -0.526 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-17 | 개시 | Goldman | Buy |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-01-02 | 개시 | H.C. Wainwright | Buy |
| 2023-08-18 | 개시 | Oppenheimer | Outperform |
| 2021-12-01 | 재개 | Jefferies | Buy |
| 2021-05-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-02-10 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-09-12 | 개시 | Mizuho | Buy |
| 2019-05-29 | 개시 | ROTH Capital | Buy |
| 2017-08-24 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | 개시 | Credit Suisse | Outperform |
| 2016-04-18 | 개시 | Guggenheim | Buy |
모두보기
Corvus Pharmaceuticals Inc 주식(CRVS)의 최신 뉴스
Corvus Pharmaceuticals (CRVS) director buys 21,700 shares and receives 15,000-share option - Stock Titan
[Form 4] Corvus Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Corvus Pharmaceuticals (CRVS) director receives grant of 15,000 stock options - Stock Titan
Director at Corvus (CRVS) receives grant of 15,000 stock options - Stock Titan
Corvus (CRVS) director awarded options for 15,000 shares at $11.60 - Stock Titan
Corvus Pharmaceuticals Faces Key Soquelitinib Data And Possible M&A Interest - Yahoo Finance
Is Corvus Pharmaceuticals, Inc. (CRVS) A Good Stock To Buy Now? - Insider Monkey
Corvus Pharmaceuticals (CRVS) posts 2026 annual shareholder meeting voting outcomes - Stock Titan
Corvus Hikes on Position in Angel - Baystreet.ca
Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China - The Manila Times
$13.5M bet on soquelitinib: China eczema and asthma trials move ahead - Stock Titan
Corvus Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside - Stocktwits
CRVS: Soquelitinib progresses in pivotal trials for PTCL and AD, targeting broad immunology markets - TradingView
Corvus Pharmaceuticals, Inc. (CRVS) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
Corvus drops after early-stage trial data for eczema therapy - MSN
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Strong One Year Gains And Recent Share Price Weakness - Sahm
Corvus Pharmaceuticals to present at major healthcare conferences in June 2026 - Pluang
Corvus (CRVS) CEO adds 6,932 shares via Miller-Horning family trust - Stock Titan
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference - marketscreener.com
Biotech Corvus heads to Jefferies and Goldman Sachs health conferences - Stock Titan
Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early (CRVS) - Seeking Alpha
Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst CallSlideshow (NASDAQ:CRVS) 2026-05-18 - Seeking Alpha
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase - sharewise.com
Boxer Capital Management's New Stake in Corvus Pharmaceuticals: SEC Filing DetailsNews and Statistics - IndexBox
Corvus Pharmaceuticals, Inc.Common Stock (NQ: CRVS - FinancialContent
Point72, Steven A. Cohen show 0% stake in Corvus (CRVS) - Stock Titan
A Quick Look at Today's Ratings for Corvus Pharmaceuticals(CRVS.US), With a Forecast Between $27 to $40 - Moomoo
Sirenia/Alex Silverstein disclose 6.83M warrant shares for Corvus (NASDAQ: CRVS) - Stock Titan
Corvus Pharmaceuticals : CRVS SID Investor Meeting Presentation FINAL - marketscreener.com
Corvus Pharmaceuticals Reports Positive Final Phase 1 Results for Soquelitinib in Atopic Dermatitis at SID 2026 Annual Meeting 16 - Minichart
Corvus drops on trial data for eczema therapy (CRVS:NASDAQ) - Seeking Alpha
Corvus Pharmaceuticals Down Over 11%, On Track for Largest Percent Decrease Since March 2025 -- Data Talk - Moomoo
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting - markets.businessinsider.com
Corvus Pharmaceuticals Unveils Positive Phase 1 Dermatitis Results - TipRanks
Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety - TradingView
Corvus (Nasdaq: CRVS) details Phase 1 soquelitinib eczema results and next trials - Stock Titan
Drug-free remissions seen after short atopic dermatitis treatment - Stock Titan
Goldman Sachs Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $40 - Moomoo
CRVS PE Ratio & Valuation, Is CRVS Overvalued - Intellectia AI
TradingKey - TradingKey
Number of shareholders of Corvus Pharmaceuticals, Inc. – NASDAQ:CRVS - TradingView
Number of shareholders of Corvus Pharmaceuticals, Inc. – TRADEGATE:C17 - TradingView
Corvus Loss, Shelf Offering and Soquelitinib Progress Might Change The Case For Investing In CRVS - Sahm
Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Return To Losses And New Shelf Offering Might Change The Case For Investing In Corvus Pharmaceuticals (CRVS) - Yahoo Finance
Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $33 - Moomoo
MSN Money - MSN
Corvus: Q1 Earnings Snapshot - theheraldreview.com
Corvus Pharmaceuticals earnings up next as AD trial looms By Investing.com - Investing.com Australia
Corvus Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Corvus Pharmaceuticals Inc (CRVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Corvus Pharmaceuticals Inc 주식 (CRVS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MILLER RICHARD A MD | President and CEO |
May 18 '26 |
Buy |
12.04 |
6,932 |
83,453 |
1,195,035 |
| Thompson Peter A. | Director |
Jan 28 '26 |
Option Exercise |
5.33 |
210,000 |
1,119,374 |
210,000 |
| ORBIMED ADVISORS LLC | Director |
Jun 27 '25 |
Sale |
4.16 |
1,176,332 |
4,891,894 |
7,165,006 |
| Thompson Peter A. | Director |
Jun 27 '25 |
Sale |
4.16 |
1,176,332 |
4,891,894 |
7,165,006 |
2.60%
0.94%
자본화:
|
볼륨(24시간):